<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002227</url>
  </required_header>
  <id_info>
    <org_study_id>281C</org_study_id>
    <secondary_id>DMP 266-043</secondary_id>
    <nct_id>NCT00002227</nct_id>
  </id_info>
  <brief_title>A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs</brief_title>
  <official_title>A Phase II, Open-Label, Multicenter Study to Characterize the Effectiveness and Safety of Efavirenz in Combination With Stavudine and Lamivudine in Antiretroviral Therapy-Naive HIV-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dupont Merck</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if it is safe and effective to give efavirenz plus
      stavudine plus lamivudine to patients who have never taken anti-HIV drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be given combination treatment with efavirenz, stavudine, and lamivudine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>60</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stavudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients must have:

          -  Documented diagnosis of HIV infection with plasma HIV-RNA greater than or equal to
             10,000 copies/ml.

          -  Life expectancy of at least 12 months.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Current bilateral peripheral neuropathy greater than or equal to Grade 2.

          -  Proven or suspected acute hepatitis due to any cause.

          -  Recurrent episodes of moderate to severe diarrhea, or vomiting lasting for more than 4
             days within 3 months prior to dosing.

          -  Hypersensitivity to any component of the formulation of efavirenz, stavudine, or
             lamivudine.

          -  Any clinically significant laboratory findings obtained during the screening
             evaluation (see laboratory values).

          -  Any clinically significant disease (other than HIV infection) or clinically
             significant findings found during the screening of medical history or physical
             examination.

          -  Any malignancy that requires systemic therapy.

          -  Any active AIDS-defining opportunistic infection or disease.

        Concurrent Medication:

        Excluded:

        Astemizole, cisapride, clarithromycin, ketoconazole, itraconazole, midazolam, rifabutin,
        rifampin, terfenadine, thalidomide, triazolam, vincristine, zalcitabine or any medications
        contraindicated for concomitant use with stavudine or lamivudine as described in the
        current information package insert.

        Patients with the following prior conditions are excluded:

          -  History of acute or chronic pancreatitis.

          -  A life expectancy of less than 12 months.

          -  Difficulty swallowing capsules/tablets.

          -  Inability to communicate effectively with study personnel.

        Prior Medication:

        Excluded:

          -  Any other experimental drug within 30 days of introducing study treatment.

          -  Vaccination within 3 weeks of screening visit.

          -  Any prior antiretroviral therapy.

          -  Interferon started within 30 days of initiating study treatment.

        Risk Behavior:

        Excluded:

        Current alcohol or illicit drug use which interferes with patient's ability to follow study
        regimen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Richard Elion</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Whitman Walker Clinic</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research Initiative of New England</name>
      <address>
        <city>Brookline</city>
        <state>Massachusetts</state>
        <zip>02445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Remington Davis Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Milton S Hersey Med Ctr / Div of Hematology</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>170330850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Ctr</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montrose Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hampton Roads Med Specialists</name>
      <address>
        <city>Hampton</city>
        <state>Virginia</state>
        <zip>23666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 1998</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Stavudine</keyword>
  <keyword>Lamivudine</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>efavirenz</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Stavudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

